2021
FGF-23 (Fibroblast Growth Factor-23) and Cardiorenal Interactions
Ivey-Miranda JB, Stewart B, Cox ZL, McCallum W, Maulion C, Gleason O, Meegan G, Amatruda JG, Moreno-Villagomez J, Mahoney D, Turner JM, Wilson FP, Estrella MM, Shlipak MG, Rao VS, Testani JM. FGF-23 (Fibroblast Growth Factor-23) and Cardiorenal Interactions. Circulation Heart Failure 2021, 14: e008385. PMID: 34689571, PMCID: PMC8782627, DOI: 10.1161/circheartfailure.121.008385.Peer-Reviewed Original ResearchConceptsFGF-23Cardiorenal interactionsHeart failureDiuretic resistanceSodium avidityNeurohormonal activationMultivariable analysisDistal tubular sodium reabsorptionLoop diuretic doseTubular sodium reabsorptionGlomerular filtration rateCardiorenal dysfunctionDiuretic doseDiuretic treatmentNT-proBNPFractional excretionDiuretic administrationSodium reabsorptionPeak diuresisFiltration rateCare centerUrine samplingAnimal modelsSerum chlorideDisease severity
2019
First in Human Experience with Direct Sodium Removal Using a Zero Sodium Peritoneal Solution
Rao V, Turner J, Mahoney D, Griffin M, Asher J, Ivey-Miranda J, Gomez N, Finkelstein F, Testani J. First in Human Experience with Direct Sodium Removal Using a Zero Sodium Peritoneal Solution. Journal Of Cardiac Failure 2019, 25: s7-s8. DOI: 10.1016/j.cardfail.2019.07.027.Peer-Reviewed Original ResearchStandard PD solutionHeart failurePeritoneal dialysisPD solutionsSignificant discomfortPeritoneal solutionsSodium removalHF animal modelsMethods 10 patientsSafety/tolerabilitySecondary efficacy endpointsPrimary endpointEfficacy endpointAdverse eventsBlood pressureSerum sodiumAlternative therapiesPeritoneal fluidPlasma glucosePlasma potassiumUltrafiltration volumeAnimal modelsIntraperitoneal volumeDSR groupVital signs